Unilife — Q2 FY2015 Earnings Presentation
15 slides from Unilife's earnings presentation, Feb 12, 2015
Slide 1: 2nd Quarter of Fiscal 2015 Earnings Call
2 nd Quarter of Fiscal 2015 Earnings Call Confidential-Unilife Corporation February 9, 2015 Exhibit 99.2
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Confidential-Unilife Corporation 2 This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management. Our manage
Slide 3: Investor Highlights: Continuing our Strong Momentum
Confidential-Unilife Corporation Investor Highlights Our large market opportunity is proven and expanding Our ability to win uniquely is well-demonstrated and gaining strength Our execution to support existing customer programs is strong and remains firmly on track Our attractive model is validated
Slide 4: Large, Growing Markets
Projected growth from $4B (2015) - $15B (2025)** CAGR 14% Wearable injectors ^ (wearable disposal self-injectors) Prefilled syringes* Auto-injectors Reconstitution Ocular delivery Novel delivery ^ Roots Resarch. Wearable Bolus Injectors. 2014. VisionGain Medical Device Leader Series 2014-2024. ** Co
Slide 5: Our Demonstrated Ability to Win Uniquely
Platform Specific Solutions Comprehensive Portfolio Robust Supply Chain with Continuity of Supply Our Demonstrated Ability to Win Uniquely Compelling Technologies Addressing unmet needs Adding value for patients, prescribers and payers Mitigating customer risk Customizable to needs of specific drugs
Slide 6: Attractive Business Model
An Attractive Business Model • Unifill Finesse for Lovenox • 10-Years • $ 50MM in upfront payments • Min. 150MM units^ • Unifill platform for 20 generic injectables • 15-Years • $ 40MM in upfront / milestone payments • Min. 175MM units^ • Unilife sole provider for all applicable wearable drugs • 5-1
Slide 7: Commercial Pipeline to Generate Incremental Growth
Commercial Pipeline to Generate Incremental Growth • In-depth product-specific discussions with customer • Multiple current and prospective customers • Multiple potential drug candidates per customer • May take 1 - 3 years to begin an active program • Device customization and other activities to pre
Slide 8: Business Execution: Case Study One, Unifill platform
Business Execution • Commercial shipments commenced ° st 1 million units prior to middle FY16 ° nd line operational ° rd line nearing completion • Shipments to accelerate FY15 - FY16 Case Study One: Unifill platform of prefilled syringes
Slide 9: Business Execution: Case Study Two, Wearable Injectors
Several customer programs underway Shipped over 80,000 devices or drug containers in H1 FY15 Scaling up capacity High-volume line with 5MM unit annual capacity Flextronics validation Begin shipping devices for human drug trials during first half FY16 Business Execution Case Study Two: Platform of We
Slide 10: Business Execution: Case Study Three, R&D Programs
Business Execution Now 180-plus patents issued worldwide. Over 200 more pending. R&D investment to improve existing technologies and create new device categories Case Study Three: R&D Programs New Patent Applications Granted Patents FY 2012 FY 2013 FY 2014 Patent return on investment is increasing f
Slide 11: Financial Results
Three Months Ended 2014 2013 Financial Results Revenues $ 5.4MM $ 3.6MM Research & development $ 11.3 MM $ 7.8MM Selling, general & administrative $ 9.5MM $ 6.7MM Net loss per share $ 0.18 $ 0.17 Adjusted net loss* $ 12.5MM $ 8.3MM Adjusted net loss per share - diluted $ 0.12 $ 0.08 * Adjusted net l
Slide 12: Increasing Cash Receipts and Revenue
Increasing Cash Receipts and Revenue Cash Receipts Revenue $ MM $ MM • $ 8MM in cash receipts from customers during the first half FY 201 5 o On schedule to generate an additional $20MM during second half FY 2015 • Additional $ 45 million from U.S. offering of common stock added in February 2015 to
Slide 13: Summary
Summary Existing Agreements • Continued scale-up to commercial launch • Commencement of new programs with additional molecules • Expected human drug studies with some target molecules Incremental Agreements • Multiple new agreements: commercial supply agreements with AbbVie and others Other Commerci
Slide 14: Questions
Confidential-Unilife Corporation Questions
Slide 15: Final Comments
Confidential-Unilife Corporation Final Comments